Sarecycline, a novel and tetracycline-derived antibiotic, is being developed for use as an oral once daily antibiotic treatment for patients suffering from moderate to severe acne vulgaris. Sarecycline has anti-inflammatory activity and the potential for a favorable tolerability profile.